Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

glasdegib

This page shows the latest glasdegib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro (dacomitinib) for locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC).

Latest news

  • Pfizer poaches cancer R&D head Jeff Settleman from Calico Pfizer poaches cancer R&D head Jeff Settleman from Calico

    That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    Last November, the drugmaker claimed FDA approval for Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC and SMO inhibitor Daurismo (glasdegib) for acute myeloid leukaemia, while in October

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    The US regulator cleared Daurismo ( glasdegib) for use in combination with low-dose cytarabine for patients with newly-diagnosed AML – aged 75 or over – who are too frail to be treated ... Analysts at Credit Suisse have previously predicted that

  • Pfizer's SMO inhibitor boosts survival in blood cancer trial Pfizer's SMO inhibitor boosts survival in blood cancer trial

    Pfizer's glasdegib has become the first SMO inhibitor to show a benefit in two haematological malignancies, boosting overall survival in a phase II trial. ... Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The FDA cleared Daurismo (glasdegib) in late November for use in combination with low-dose cytarabine for patients with newly-diagnosed AML – aged 75 or over – who are too frail to ... Analysts at Credit Suisse have predicted approval in AML could

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
The Creative Engagement Group

We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...

Latest intelligence

Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Quick links